{"entity":{"id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of AZD9793 in hepatocellular carcinoma, run by AstraZeneca, now recruiting.","summary":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours is a phase 1/2 interventional study registered as NCT06795022 by AstraZeneca, with 304 participants planned, started 2025-03-27 and due to reach its primary completion in 2027-06-30. Interventions recorded: AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06795022","url":"https://clinicaltrials.gov/study/NCT06795022"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["azd9793"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06795022","phase":"1/2","setting":"A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)","sponsor":"AstraZeneca","enrolled":304,"outcomes":[]},"route":"/trials/nct06795022/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}